Author: Jane Edwards|| Date Published: December 28, 2016
Four companies have won spots on a potential 10-year, $159 million contract to provide preclinical drug development support services for the National Institute of Allergy and Infectious Diseases.
The multiple-award, indefinite-delivery/indefinite-quantity contract covers the development of manufacturing processes and analytical test procedures, regulatory services, manufacturing and product characterization in support of the development of biopharmaceutical drug candidates for infectious diseases, the National Institutes of Health said in a FedBizOpps notice.
Stockholders of semiconductor foundry SkyWater Technology have approved the company’s merger with quantum computing company IonQ. Quantum computing and post-quantum…
Kris Levin-Snow, area vice president within AT&T‘s national security group, will now oversee the company’s defense industrial base portfolio in addition…
Rocket Lab has signed a definitive agreement to acquire California-based Motiv Space Systems, adding space robotics and precision spacecraft mechanism…
Four companies have won spots on a potential 10-year, $159 million contract to provide preclinical drug development support services for the National Institute of Allergy and Infectious Diseases.
